Akinsanya Karen
SEC CIK 1797672 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SDGR | Schrodinger, Inc. | See Remarks | 101.6K | — | $3.73M | 14 | 2021-08-16 | 2026-09-17 |
Most active insiders at SDGR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Farid Ramy | Pres, CEO, Dir | — | $1.17M |
| 2 | Akinsanya Karen | See Remarks | — | $972.0K |
| 3 | Jain Rachit | EVP, CFO | — | $45.4K |
| 4 | Abel Robert Lorne | See Remarks | — | $33.3K |
| 5 | Dugan Margaret | Chief Medical Off | — | $29.4K |
| 6 | Lorton Kenneth Patrick | EVP, CTO, COO, Software | — | $28.5K |
| 7 | Herman Jenny | CAO | — | $28.1K |
| 8 | Tran Yvonne | EVP, CLO, CPO | — | $24.8K |
| 9 | Aklian Mannix Vartan | See Remarks | — | — |
| 10 | Friesner Richard | Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-21 17:15 | 2026-09-17 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | M - OptEx | $4.34 | +31.6K | 101.6K | +45% | +$137.1K |
| DMT | 2026-09-21 17:15 | 2026-09-17 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale+OE | $29.37 | -31.6K | 70.0K | -31% | -$928.0K |
| 2026-03-06 | 2026-03-05 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale | $12.90 | -1,366 | 70.0K | -2% | -$17.6K | |
| DM | 2026-03-03 | 2026-03-02 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | A - Grant | $0.00 | +57.9K | 46.0K | New | $0 |
| D | 2026-03-03 | 2026-03-02 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale | $11.99 | -2,206 | 71.3K | -3% | -$26.4K |
| DM | 2025-04-15 | 2025-04-14 | SDGR | Schrodinger, Inc. | Akinsanya Karen | Pres of R, D, Therapeutics | S - Sale+OE | $25.09 | -16.7K | 15.6K | -52% | -$419.5K |
| DM | 2025-04-15 | 2025-04-14 | SDGR | Schrodinger, Inc. | Akinsanya Karen | Pres of R, D, Therapeutics | M - OptEx | $3.16 | +16.7K | 32.3K | +107% | +$52.8K |
| D | 2025-03-04 | 2025-03-03 | SDGR | Schrodinger, Inc. | Akinsanya Karen | Pres of R, D, Therapeutics | A - Grant | $0.00 | +15.6K | 15.6K | New | $0 |
| D | 2021-10-19 | 2021-10-15 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale+OE | $55.75 | -1,393 | 0 | -100% | -$77.7K |
| D | 2021-10-19 | 2021-10-15 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | M - OptEx | $4.34 | +1,393 | 1,393 | New | +$6,046 |
| D | 2021-09-16 | 2021-09-15 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale+OE | $61.13 | -1,394 | 0 | -100% | -$85.2K |
| D | 2021-09-16 | 2021-09-15 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | M - OptEx | $4.34 | +1,394 | 1,394 | New | +$6,050 |
| DM | 2021-08-17 | 2021-08-16 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | S - Sale+OE | $57.74 | -37.7K | 0 | -100% | -$2.18M |
| DM | 2021-08-17 | 2021-08-16 | SDGR | Schrodinger, Inc. | Akinsanya Karen | See Remarks | M - OptEx | $10.71 | +37.7K | 37.7K | New | +$404.3K |
Purchase Sale Sale after option exercise All abbreviations